in the juvenile form. 13, 14 Instead, for unclear reasons, in JHD dystonia, rigidity, mental retardation, and epileptic seizures occur. [15] [16] [17] There is no cure or disease-modifying treatment for either form of HD, and most pharmacological treatments are palliative; thus, there is an urgent need to find alternative therapies.
The main histopathological feature of HD is the loss of striatal medium-sized spiny neurons (MSNs). 18 However, with disease progression, neurons in the cerebral cortex, hippocampus, hypothalamus, and thalamus also are lost. 19 Normal brains have two striatal projection pathways, each with distinct MSN populations expressing different types of dopamine receptors and neuropeptides. 20 The direct pathway projects to the substantia nigra pars reticulata and the internal segment of the globus pallidus, whereas the indirect pathway projects to the external segment of the globus pallidus which, in turn, projects to the subthalamic nucleus. 21, 22 It is believed that MSNs giving rise to the indirect pathway are more vulnerable and degenerate before MSNs giving rise to the direct pathway, leading to an imbalance between both pathways and the emergence of involuntary movements. 23, 24 In addition, although HD mainly affects projection neurons in striatum and cortex, recent studies have reported that parvalbumin interneurons also are vulnerable to the disease and eventually degenerate. 25 Other types of GABAergic interneurons, including those expressing somatostatin and calretinin, are protected. The large striatal cholinergic interneurons, although preserved in HD, display morphological and functional alterations. [26] [27] [28] At present, it remains unknown why striatal MSNs are the most susceptible to degeneration although several hypotheses have been proposed. [29] [30] [31] [32] [33] Most likely, MSN degeneration occurs due to lack of neurotrophic support, 34, 35 as well as alterations in glutamate release along the corticostriatal pathway or abnormal sensitivity and localization of N-methyl-D-aspartate (NMDA) receptors. [36] [37] [38] [39] [40] [41] [42] Ultimately, the important question is how can we prevent and/or replace cell degeneration and loss in HD brains.
Grafting of mouse and human fetal striatal tissue obtained from animal and human embryos as a potential treatment has been tested in animal models of HD [43] [44] [45] [46] and in human patients (for a review, see Ref. 47) , respectively, but the success of this approach has been variable and ethical issues as well as tissue availability raise important concerns. 48, 49 The emergent field of regenerative medicine offers renewed hope for cell replacement therapies and provides new approaches for a potential cure. In particular, the use of human embryonic stem cells (hESCs) and induced pluripotent stem cell (iPSC)-derived products has generated widespread interest for neurodegenerative diseases including HD. [50] [51] [52] In this review, we present recent advances in the use of various stem cell types in animal models of HD. In addition, we provide further electrophysiological characterization of ESI-017
human neural stem cells (hNSCs), a good manufacturing practice (GMP)-grade cell line which has already shown promising results in two HD mouse models. 53 Before reviewing the use of stem cells in HD research, we will briefly describe the animal models used in these studies.
| RODENT MODEL S OF HD US ED FOR S TEM CELL RE S E ARCH

| Lesion models
Many of the early rodent models used for studying HD involved the injection of chemical toxins. Intrastriatal injection of quinolinic acid (QA), an NMDA receptor agonist, became a popular model due to its ability to replicate the striatal histopathology of HD.
In high doses, QA destroys local MSNs while sparing axons and some types of interneurons. 54 Although lesioned rats did not display chorea, they exhibited hyperkinesia, dystonia, and dyskinesia.
Moreover, QA-lesioned rats showed spatial and cognitive impairments when tested in the Morris water maze and the T-maze. 55 The advantage of the QA model is largely related to the glutamatergic excitotoxic method of striatal death thought to happen in patients with HD. 56 3-nitropropionic acid (3-NP) induces cell death via mitochondrial impairment. It inhibits the enzyme succinate dehydrogenase, leading to the accumulation of reactive oxygen species. 57 This impairment is also seen in patients with HD and thus provides another method for studying the disease in rodent models. 58 The toxin is injected subcutaneously and induces hyperkinesia at low doses and hypokinesia at high doses, as well as cognitive impairments related to memory and attention. 57 Toxin-induced models helped to elucidate the process of cell death in HD, but they are limited in that they do not allow the study of disease progression or dysfunctional changes before any obvious neurodegeneration.
| N-terminal transgenic models
In comparison with toxin-induced models, genetic rodent models of HD provide a more specific and deeper understanding of the behavioral and physiological progression of the phenotype. 59 
| Knock-in models
Knock-in (KI) models differ from transgenic models in that they express the mutation within the endogenous genomic locus. Many KI models have been produced that vary based on their CAG repeat length, in which the allele for the mouse HTT exon 1 is replaced by the human mutant variant. For example, the CAG140 has 140 polyglutamine repeats added to the mouse HTT gene. By 1-4 months of age, these mice show many motor and behavioral deficits, with loss of striatal volume by 2 years. 67, 68 Moreover, homozygotes for the mutation show more severe symptoms than those heterozygous for the mutation. The similarity in phenotype to human HD, their longer life span, and the gradual progression of disease-related symptoms make KI models useful for studying HD, as well as in evaluating longterm grafting of stem cells. 
| S TEM CELL G R AF TS IN HD MODEL S
| Mesenchymal stem cells
The use of adult multipotent stem cells, which includes adipose-and bone marrow-derived MSCs, has been a widely used approach for stem cell transplantation therapy for HD due to their ability to differentiate into a wide variety of cell types, [79] [80] [81] are readily accessible, are relatively safe as they are not pluripotent and therefore not tumorigenic, are thought to be immune privileged, and do not pose ethical concerns over their use in treatment of disease. 82 However, their effects may also be relatively transient due to cell survival limitations and altered in vivo performance following long-term exposure to ex vivo culturing environments prior to transplantation. 83 MSCs secrete many bioactive substances that assist in the repair and regeneration of damaged tissue by reducing inflammation, inhibiting apoptosis, and stimulating angiogenesis. 84 Injection of MSCs into the striatum of 3-NP lesioned rats improved their motor function and extended their life span, 85 while transplantation into QA-lesioned rats resulted in a reduction in cognitive deficits shortly following implantation.
86
Human adipose-derived MSCs implanted bilaterally into the striata of R6/2 mice showed improved motor function and increased survival time. 87 Following transplantation, the presence of mhtt aggregates and the rate of striatal apoptosis declined. The same type of MSCs was later implanted in YAC128 mice to study their long-term effects on disease progression. 88 When transplanted prior to the presence of disease-related symptoms, no therapeutic improvement was apparent. When transplanted after the presentation of symptoms, the mice showed motor improvement on the rotarod test. One of the beneficial actions of this method lies in the fact that MSCs release multiple trophic factors, including brain-derived neurotrophic factor (BDNF), which is decreased in patients with HD. 35 When
MSCs engineered to overexpress BDNF were implanted into the striatum of YAC128 mice, some behavioral and pathological deficits were reduced. 88 When these cells were introduced into R6/2 mice, they increased their life span and promoted endogenous neurogenesis. 89, 90 While increased levels of trophic factors by MSCs encourage the growth of axons and cell attachment, the ability of these cells to differentiate into mature neurons and establish synaptic communication with other neurons in vivo remains controversial. 
| Pluripotent stem cells
PSCs, which can be differentiated into each of the three germ line lineages, provide an alternative therapeutic option for the treatment of HD. Human PSCs, both embryonic and induced patient fibroblasts, can be differentiated in culture to neurons with and implanted into striata of 10-month-old YAC128 mice, 96 there was an improvement in motor abilities over the span of 10 weeks following implantation. In addition, the stem cells survived and differentiated into mature MSNs. Moreover, BDNF protein and receptor levels significantly increased in the striatum of the treated mice. However, for diseases such as HD, the mutation is present in all cells; therefore, transplantation would require modification of the cells as they could promote disease or more readily take on HD phenotypes. One such study showed that HD patient-derived iPSCs could be differentiated into GABAergic striatal neurons, in vitro. These cells were then transplanted into unilateral QAlesioned mice. 97 Initially, the cells did not form mhtt aggregates. By 33 weeks, however, after stem cell grafts were fully integrated into the host tissue, the iPSC-NSCs showed signs of pathology including mhtt aggregates. Nevertheless, the QA-lesioned mice exhibited behavioral and motor recovery for weeks following transplantation.
An alternative strategy of replacing the CAG expansion cassette in HD patient-derived iPSCs with one of normal repeat length via homologous recombination showed potential for correcting the recurring pathology seen in iPSCs derived from HD patients. 94 The cells grew in vitro into mature DARPP-32-expressing MSNs that were then implanted into R6/2 mice. These cells survived 2 weeks post-transplantation, continued to express DARPP-32, and normalized cadherin, TGF beta, BDNF, and caspase signaling pathways, supporting feasibility of this type of gene correction approach of patient-derived iPSCs.
| Embryonic stem cell (ESC)-derived products
Other In vitro, ESC-derived NSCs have the ability to modulate inflammation, particularly by reducing the responses that follow T-cell receptor, IL2, and IL6 activation. 103 One HD study showed that the secretion of growth factors from mouse-derived embryonic NSCs plays a vital role in their ability to support QA-lesioned rat striatal neurons. When stimulated by epidermal growth factor (EGF), human nerve growth factor (hNGF)-releasing NSCs reduced the size of the striatal lesion, prevented the loss of GABAergic MSNs, and thus helped maintain the overall circuitry of the striatum. 104 The presence of hNGF-secreting NSCs likely provides neuroprotection to the neurons most greatly affected in individuals with HD. 102 The likely cause of this difference in greater efficacy in lesioned mice versus transgenic models may be the higher stem cell survival in QA-lesioned mice than in the R6/2 or N171-82Q mice.
Although it is unclear why stem cell survival was increased in the In both models, hNSCs were implanted during the presymptomatic stage, supporting the idea that the time of implantation may influence therapeutic outcomes. hNSCs clustered along the needle track and were well-circumscribed to the injection site. The demarcation between implant and host tissue was also distinct due to the myelin presence in the host tissue, which produces a darker image under IR-DIC microscopy. The localization of hNSCs within the implant was further corroborated by immunostaining with the human stem cell marker, SC121 ( Figure 1A ).
| ESI-017-derived hNSCs
hNSCs were densely packed, and most cell bodies appeared healthy under IR-DIC optics. Short processes were sometimes visible. hNSCs recorded in striatum displayed basic neuronal properties characteristic of immature neurons. Cell membrane capacitance was small, the input resistance was very high, and the decay time constant was relatively fast, <1 ms (Table 2 ). In contrast, host MSNs displayed much larger capacitances, smaller membrane input resistances, and time constants >1 ms. 53 In cell-attached mode, some hNSCs generated action potentials spontaneously ( Figure 1B ), but most of them were silent. However, Statistical significance determined using Student's t tests, where * and ** indicate P < 0.05 and P < 0.01, respectively, for comparisons made between genotypes for each structure.
TA B L E 2 Passive membrane properties of hNSCs in the striatum and cerebral cortex panel). hNSCs displayed spontaneous excitatory and inhibitory postsynaptic currents (sEPSCs and sIPSCs), indicating that they received synaptic inputs from the host tissue or from other implanted hNSCs ( Figure 1D ). However, compared with MSNs, frequencies were much lower: <0.1 Hz on average for NSCs (range 0.01-0.7 Hz) vs ~3 Hz on average for MSNs (range 0.6-10 Hz). To further assess whether hNSCs receive synaptic inputs, the striatum was electrically stimulated with a monopolar electrode placed in the slice ~150 μm away from recorded hNSCs. A short duration stimulus (0.5 ms, 0.1 mA)
yielded a small outward current at positive holding potentials that was subsequently blocked completely by the GABA A receptor antagonist Bicuculline (10 μmol/L), confirming that these cells receive GABAergic synaptic inputs. It remains unknown whether these inputs come from other hNSCs and/or cells from the host tissue as the stimulation of most striatal cells produces a GABA response.
Nevertheless, it is clear that grafted hNSCs have the ability to receive inputs from local circuits. In addition, Reidling et al 53 showed
that using electron microscopy analysis, synaptic connections were being formed with the host tissue for a subset of transplanted cells.
In HD, cortical pyramidal neurons (CPNs) also degenerate.
Accordingly, in our studies we tested the properties of hNSCs implanted in the cerebral cortex. Similar to hNSCs implanted in striatum, those implanted in motor cortex could be easily identified by their reduced capacitance, high membrane input resistance, and fast time constant (Table 2 ). Figure 2A shows a cortical graft and illustrates the clear demarcation between implanted and host tissue One important question is whether or not the disease process affects the development and properties of hNSCs. We noticed the cell capacitance was reduced and the input resistance was increased in hNSCs implanted in the striatum of R6/2 mice, suggesting reduced membrane area. In the cortex, there were no differences in cell capacitance or membrane time constants of hNSCs implanted in WT and R6/2 mice, but there was an increase in the input resistance of hNSCs in R6/2 mice (Table 2 ). This probably indicates that the local environment in the striatum of R6/2 mice is less favorable than in control mice or in cerebral cortex. There also was a significant difference in the capacitance between hNSCs in the striatum versus the cortex (P < 0.001, two-way ANOVA).
Overall the data indicate that hNSCs 4-6 weeks following implantation in WT and R6/2 mice are viable, integrate well in the host striatum and cortex, and display neuronal, although still immature, passive, and active membrane properties. In addition, they receive excitatory and inhibitory synaptic inputs and have the potential to modulate the activity of other hNSCs and probably also host neurons as they are capable of firing action potentials. The question is whether this is sufficient to modulate disease progression and rescue some of the electrophysiological changes in HD models.
| Effects of hNSCs on membrane properties of host striatal projection neurons
MSNs recorded in symptomatic R6/2 mice display reduced membrane capacitance and increased input resistance, caused in part by reduced somatic area, loss of spines, and reduced K + channel expression. [111] [112] [113] Implantation of hNSCs did not prevent alterations in cell membrane properties of MSNs recorded near the injection site ( Statistical significance determined using a one-way ANOVA followed by Holm-Sidak post hoc analyses, where * and ** indicate P < 0.05 and P < 0.01, respectively, for comparisons made between R6/2 treatment groups and WT. † Indicates P < 0.05 for comparisons made between R6/2 treatment groups.
TA B L E 3 Passive membrane properties of MSNs in the striatum for BDNF. This suggests that these differentiated stem cells produced the neurotrophic factor(s) that aid in providing a supportive local environment for neurons. In addition, ESI-017 hNSCs reduced aberrant accumulation of a high molecular weight, potentially toxic form of mhtt protein in the striatum of transplanted animals.
| CON CLUS I ON S , LIMITATI ON S , AND FUTURE PER S PEC TIVE S
We have presented an extensive, but not exhaustive, review of studies using stem cells that have demonstrated positive effects on neuro logical, cognitive, and electrophysiological alterations in rodent models of HD. In addition, we provide additional characterization of the GMP-grade human ESI-017 line of NSCs that when implanted into HD mice are able to remain viable and electrophysiologically active for weeks in vivo. They also have the ability to establish synaptic connections. 53 With so many stem cell options, it is difficult to determine which type would serve as the best therapy for neurodegenerative diseases, such as HD. A limitation to using F I G U R E 3 Implantation with hNSCs in striatum reduced paroxysmal discharges induced by Bicuculline: A, Bath application of the GABA A receptor antagonist Bicuculline (10-20 μmol/L) induced epileptiform activity in striatal MSNs. This activity was expressed in the form of large-amplitude synaptic currents followed by transient bursts of low-amplitude EPSCs (arrows). In mice implanted with hNSCs, the amplitude and frequency of these events were reduced and the transient low-amplitude EPSCs displayed reduced frequencies. B, Inset shows a magnified view of the paroxysmal discharges taken from the dotted rectangles in A and should also be considered as potential cell differentiation candidates in stem cell-based therapies for HD.
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